AU2019338582B2 - New conjugates of montelukast and peptides - Google Patents

New conjugates of montelukast and peptides

Info

Publication number
AU2019338582B2
AU2019338582B2 AU2019338582A AU2019338582A AU2019338582B2 AU 2019338582 B2 AU2019338582 B2 AU 2019338582B2 AU 2019338582 A AU2019338582 A AU 2019338582A AU 2019338582 A AU2019338582 A AU 2019338582A AU 2019338582 B2 AU2019338582 B2 AU 2019338582B2
Authority
AU
Australia
Prior art keywords
virus
hyp
lys
compound
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019338582A
Other languages
English (en)
Other versions
AU2019338582A1 (en
Inventor
Ming Gu
Bengt Ingemar Samuelsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangyin Usun Pharmaceutical Co Ltd
Original Assignee
Jiangyin Usun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Usun Pharmaceutical Co Ltd filed Critical Jiangyin Usun Pharmaceutical Co Ltd
Publication of AU2019338582A1 publication Critical patent/AU2019338582A1/en
Application granted granted Critical
Publication of AU2019338582B2 publication Critical patent/AU2019338582B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019338582A 2018-09-14 2019-09-14 New conjugates of montelukast and peptides Active AU2019338582B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018105703 2018-09-14
CNPCT/CN2018/105703 2018-09-14
CN2018119072 2018-12-04
CNPCT/CN2018/119072 2018-12-04
PCT/CN2019/105832 WO2020052677A1 (en) 2018-09-14 2019-09-14 New conjugates of montelukast and peptides

Publications (2)

Publication Number Publication Date
AU2019338582A1 AU2019338582A1 (en) 2020-11-19
AU2019338582B2 true AU2019338582B2 (en) 2026-01-15

Family

ID=69777394

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019338582A Active AU2019338582B2 (en) 2018-09-14 2019-09-14 New conjugates of montelukast and peptides

Country Status (27)

Country Link
US (2) US11680082B2 (cg-RX-API-DMAC7.html)
EP (2) EP3678705B1 (cg-RX-API-DMAC7.html)
JP (1) JP7759693B2 (cg-RX-API-DMAC7.html)
KR (1) KR102946621B1 (cg-RX-API-DMAC7.html)
CN (2) CN111601618A (cg-RX-API-DMAC7.html)
AU (1) AU2019338582B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004823A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112420A1 (cg-RX-API-DMAC7.html)
DK (1) DK3678705T5 (cg-RX-API-DMAC7.html)
ES (1) ES2956509T3 (cg-RX-API-DMAC7.html)
FI (1) FI3678705T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230946T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062848T2 (cg-RX-API-DMAC7.html)
IL (1) IL281426A (cg-RX-API-DMAC7.html)
LT (1) LT3678705T (cg-RX-API-DMAC7.html)
MX (1) MX2021002657A (cg-RX-API-DMAC7.html)
MY (1) MY205435A (cg-RX-API-DMAC7.html)
PL (1) PL3678705T3 (cg-RX-API-DMAC7.html)
PT (1) PT3678705T (cg-RX-API-DMAC7.html)
RS (1) RS64436B1 (cg-RX-API-DMAC7.html)
SA (1) SA521421448B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202102119RA (cg-RX-API-DMAC7.html)
SI (1) SI3678705T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300210T1 (cg-RX-API-DMAC7.html)
TW (1) TWI875712B (cg-RX-API-DMAC7.html)
WO (1) WO2020052677A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101398B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
EP4028409A4 (en) * 2019-09-14 2023-10-11 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. NEW PEPTIDES
US20240218016A1 (en) * 2019-12-02 2024-07-04 Shenzhen Institutes Of Advanced Technology Peptides and their use in the treatment of inflammation
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2021207606A1 (en) * 2020-04-10 2021-10-14 University Of Georgia Research Foundation, Inc. Methods for treatment of coronavirus infections
KR102596264B1 (ko) * 2020-11-30 2023-11-01 주식회사 바이오빛 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
WO2022193185A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates
WO2023225107A1 (en) * 2022-05-17 2023-11-23 Emory University Diroximel fumarate, inhalation administration methods, pharmaceutical uses and compositions
JP2026506026A (ja) * 2023-02-13 2026-02-20 エンリティザ(シャンハイ)ファーマシューティカル カンパニー リミテッド 新規多機能オリゴペプチド
AU2024312518A1 (en) * 2023-06-22 2026-01-22 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
CN122028898A (zh) * 2023-10-23 2026-05-12 艾缇亚(上海)制药有限公司 新型短链肽及其衍生物
WO2025110754A1 (ko) * 2023-11-22 2025-05-30 한도숙 상처 치료 또는 피부 주름형성 억제용 조성물
WO2025195444A1 (en) 2024-03-20 2025-09-25 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New use of peptides derived from vasoactive intestinal peptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020200A2 (en) * 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2004005309A2 (en) 2002-07-08 2004-01-15 Pliva - Istrazivacki Institut D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 il­9 항체 및 그의 용도
US7582297B2 (en) * 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
JP2007510621A (ja) 2003-07-29 2007-04-26 シグニチャー アールアンドディー ホールディングス,エルエルシー. アミノ酸プロドラッグ
DE602005018672D1 (de) * 2004-10-27 2010-02-11 Glaxosmithkline Zagreb Konjugate mit entzündungshemmender aktivität
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CA2773737C (en) * 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
CN102068432A (zh) 2011-01-11 2011-05-25 李仲昆 一种由他定类和白三烯拮抗剂组成的外用复方组合物
HK1207562A1 (en) 2012-01-18 2016-02-05 苏州泰飞尔医药有限公司 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
EP2968309A4 (en) * 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
US20160060328A1 (en) * 2013-10-25 2016-03-03 Lpath, Inc. Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
BR112018000953A2 (pt) 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
CN110945016A (zh) 2017-05-24 2020-03-31 特拉斯福特普拉斯公司 用于治疗炎性疾病的肽化合物、缀合化合物及其用途
CA3068818A1 (en) * 2017-07-05 2019-01-10 Jiangyin Mucocare Pharmaceutical Co., Ltd Topical formulations comprising montelukast and combinations with mussel adhesive proteins
CN110139662B (zh) * 2017-07-05 2022-03-18 江阴贝瑞森制药有限公司 肽的抗炎用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020200A2 (en) * 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains

Also Published As

Publication number Publication date
WO2020052677A1 (en) 2020-03-19
MX2021002657A (es) 2021-07-21
ES2956509T3 (es) 2023-12-22
EP3678705A4 (en) 2021-06-09
JP7759693B2 (ja) 2025-10-24
TW202023623A (zh) 2020-07-01
PL3678705T3 (pl) 2023-10-09
PT3678705T (pt) 2023-07-19
ZA202101398B (en) 2022-09-28
SG11202102119RA (en) 2021-04-29
US11680082B2 (en) 2023-06-20
HUE062848T2 (hu) 2023-12-28
KR20210061372A (ko) 2021-05-27
EP3678705A1 (en) 2020-07-15
US20230348536A1 (en) 2023-11-02
RS64436B1 (sr) 2023-09-29
CN116785447B (zh) 2024-11-22
DK3678705T3 (en) 2023-06-26
IL281426A (en) 2021-04-29
SMT202300210T1 (it) 2023-09-06
MY205435A (en) 2024-10-21
SI3678705T1 (sl) 2023-10-30
JP2022500437A (ja) 2022-01-04
CN116785447A (zh) 2023-09-22
SA521421448B1 (ar) 2024-03-14
EP4253404A2 (en) 2023-10-04
CA3112420A1 (en) 2020-03-19
AU2019338582A1 (en) 2020-11-19
EP3678705B1 (en) 2023-05-31
EP4253404A3 (en) 2023-12-13
DK3678705T5 (da) 2024-09-16
FI3678705T3 (fi) 2023-07-04
HRP20230946T1 (hr) 2023-11-24
US20210309696A1 (en) 2021-10-07
CN111601618A (zh) 2020-08-28
LT3678705T (lt) 2023-08-10
KR102946621B1 (ko) 2026-04-01
TWI875712B (zh) 2025-03-11
BR112021004823A2 (pt) 2021-06-08

Similar Documents

Publication Publication Date Title
US20230348536A1 (en) Conjugates of montelukast and peptides
US20250041377A1 (en) Pharmaceutical use
US12612430B2 (en) Peptides
US20240218016A1 (en) Peptides and their use in the treatment of inflammation
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
HK40101414A (en) Conjugates of montelukast and peptides
RU2838061C9 (ru) Новые конъюгаты монтелукаста и пептидов
RU2838061C2 (ru) Новые конъюгаты монтелукаста и пептидов
HK40033390A (en) Conjugates of montelukast and peptides
HK40033390B (en) Conjugates of montelukast and peptides
MD3678705T2 (ro) Conjugați de montelukast și peptide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)